GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clene Inc (FRA:84C) » Definitions » Beneish M-Score

Clene (FRA:84C) Beneish M-Score : -3.78 (As of May. 06, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Clene Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.78 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Clene's Beneish M-Score or its related term are showing as below:

FRA:84C' s Beneish M-Score Range Over the Past 10 Years
Min: -3.78   Med: -3.09   Max: -2.4
Current: -3.78

During the past 5 years, the highest Beneish M-Score of Clene was -2.40. The lowest was -3.78. And the median was -3.09.


Clene Beneish M-Score Historical Data

The historical data trend for Clene's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clene Beneish M-Score Chart

Clene Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
- - - -2.40 -3.78

Clene Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.40 -3.25 -2.01 -2.70 -3.78

Competitive Comparison of Clene's Beneish M-Score

For the Biotechnology subindustry, Clene's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clene's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clene's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Clene's Beneish M-Score falls into.



Clene Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Clene for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.331+0.528 * 1.1574+0.404 * 0.8748+0.892 * 1.3239+0.115 * 0.5557
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.5988+4.679 * -0.242807-0.327 * 0.8211
=-3.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was €1.23 Mil.
Revenue was 0.156 + 0.101 + 0.248 + 0.1 = €0.61 Mil.
Gross Profit was 0.121 + 0.09 + 0.187 + 0.095 = €0.49 Mil.
Total Current Assets was €35.63 Mil.
Total Assets was €48.00 Mil.
Property, Plant and Equipment(Net PPE) was €12.32 Mil.
Depreciation, Depletion and Amortization(DDA) was €1.58 Mil.
Selling, General, & Admin. Expense(SGA) was €12.15 Mil.
Total Current Liabilities was €23.23 Mil.
Long-Term Debt & Capital Lease Obligation was €11.05 Mil.
Net Income was -9.329 + -2.266 + -23.207 + -10.993 = €-45.80 Mil.
Non Operating Income was 0.402 + 7.045 + -13.159 + -0.428 = €-6.14 Mil.
Cash Flow from Operations was -6.577 + -6.334 + -6.48 + -8.61 = €-28.00 Mil.
Total Receivables was €2.80 Mil.
Revenue was 0.221 + 0.176 + 0.033 + 0.027 = €0.46 Mil.
Gross Profit was 0.214 + 0.157 + 0.033 + 0.027 = €0.43 Mil.
Total Current Assets was €27.56 Mil.
Total Assets was €42.00 Mil.
Property, Plant and Equipment(Net PPE) was €14.39 Mil.
Depreciation, Depletion and Amortization(DDA) was €0.97 Mil.
Selling, General, & Admin. Expense(SGA) was €15.33 Mil.
Total Current Liabilities was €13.08 Mil.
Long-Term Debt & Capital Lease Obligation was €23.45 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(1.227 / 0.605) / (2.8 / 0.457)
=2.028099 / 6.126915
=0.331

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(0.431 / 0.457) / (0.493 / 0.605)
=0.943107 / 0.814876
=1.1574

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (35.627 + 12.316) / 47.997) / (1 - (27.56 + 14.387) / 42.001)
=0.001125 / 0.001286
=0.8748

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=0.605 / 0.457
=1.3239

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.971 / (0.971 + 14.387)) / (1.581 / (1.581 + 12.316))
=0.063224 / 0.113766
=0.5557

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(12.152 / 0.605) / (15.33 / 0.457)
=20.08595 / 33.544858
=0.5988

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((11.054 + 23.228) / 47.997) / ((23.453 + 13.081) / 42.001)
=0.714253 / 0.869836
=0.8211

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-45.795 - -6.14 - -28.001) / 47.997
=-0.242807

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Clene has a M-score of -3.83 suggests that the company is unlikely to be a manipulator.


Clene (FRA:84C) Business Description

Traded in Other Exchanges
Address
6550 South Millrock Drive, Suite G50, Salt Lake City, UT, USA, 84121
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. Its reportable segments: (1) the development and commercialization of novel clean-surfaced nanotechnology therapeutics (Drugs, and (2) the development and commercialization of dietary supplements (Supplements).

Clene (FRA:84C) Headlines

No Headlines